Table 2. Patient demographics and clinical data of the low and non-low BMI groups.
| Variable | Low BMI group (<18.5 kg/m2) (n = 103) | Non-low BMI group (≥18.5 kg/m2) (n = 445) | p-value |
|---|---|---|---|
| BMI (kg/m2), median (IQR) | 16.8 (15.7–17.6) | 22.9 (21.0–25.6) | <0.001 |
| Age (years), median (IQR) | 79 (68–86) | 73 (64–82) | 0.003 |
| Male, n (%) | 63 (61.2) | 282 (63.4) | 0.73 |
| Pre-existing conditions, n (%) | |||
| Cardiovascular disease | 12 (11.7) | 61 (13.7) | 0.63 |
| Stroke | 17 (16.5) | 60 (13.5) | 0.43 |
| COPD | 7 (6.8) | 12 (2.7) | 0.065 |
| Autoimmune disease | 4 (3.9) | 25 (5.6) | 0.63 |
| Chronic liver disease | 1 (1.0) | 17 (3.8) | 0.22 |
| Diabetes mellitus | 21 (20.4) | 143 (32.1) | 0.023 |
| Chronic kidney disease | 7 (6.8) | 48 (10.8) | 0.28 |
| Malignancy | 13 (12.6) | 44 (9.9) | 0.47 |
| Medications before admission, n (%) | |||
| Steroids | 10 (9.7) | 59 (13.3) | 0.41 |
| Immunosuppressant drugs | 2 (1.9) | 20 (4.5) | 0.40 |
| Statins | 10 (9.7) | 69 (15.6) | 0.161 |
| Anti-platelets | 16 (15.5) | 79 (17.8) | 0.67 |
| β-blockers | 14 (13.6) | 48 (10.8) | 0.49 |
| Severity | |||
| Lactate (mmol/L), median (IQR) | 2.75 (2.08–4.03) | 2.70 (1.90–4.40) | 0.99 |
| Septic shock, n (%) | 60 (58.8) | 242 (55.1) | 0.51 |
| APACHE II score, median (IQR) | 20 (15–26) | 19 (15–26) | 0.57 |
| SOFA score, median (IQR) | 7 (5–11) | 8 (5–11) | 0.34 |
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment.